Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 172   

Articles published

PFE 31.94 0.00 (0.00%)
price chart
Interesting March 2015 Stock Options for Pfizer
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer PFE -0.09% Inc (NYSE: PFE). So this week we highlight one interesting put contract, and one interesting call contract, from ...
Related articles »  
Stock Update: Pfizer Inc. (NYSE:PFE)
[The Fly] Pfizer Inc. (NYSE:PFE) announced top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release formulation in adult patients with postherpetic neuralgia.
Pfizer Inc. (PFE) Closes 0.66% Down on the Day for December 11
Dow Jones component Pfizer Inc. (PFE) saw its stock move -0.66% to $31.65, representing a per-share move of $0.21, on volume of 24.83 million shares for Thursday.
Related articles »  
Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug
Pfizer Inc. (NYSE:PFE) yesterday announced positive results for its Phase III study evaluating pregabalin controlled-release (CR) treatment, marketed as Lyrica, as a treatment for postherpetic neuralgia, or pain due to nerve damage.
Pfizer, OPKO Health partner on growth-hormone treatment
Pfizer Inc. and OPKO Health Inc. have partnered to develop and commercialize an OPKO treatment for growth-hormone deficiency that could replace daily injections with weekly ones.
OPKO Up on Announcing Global Partnership with Pfizer - Analyst Blog  Nasdaq
Related articles »  
Pfizer Reports Statistically Significant Results for Nerve-Pain Treatment
Pfizer Inc. said a study of its pregabalin controlled-release treatment showed patients taking it for nerve pain showed improvement compared with those who took a placebo.
Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin ...  Finances.com
Related articles »  
Pfizer (NYSE:PFE) Obtains Commercial Rights to Human Growth Hormone
Pfizer Inc. (NYSE:PFE) struck a deal with Opko in a multi-thousand dollar deal in which the latter would help Pfizer Inc. (NYSE:PFE) deal with the rising competition by providing commercial rights to the human hormone drugs. Pfizer Inc. (NYSE:PFE) is ...
Pfizer's Lyrica Doesn't Help Most Common Back Pain, Study Finds
Pfizer Inc. (PFE)'s best-selling drug, Lyrica, didn't help patients with the most common cause of back pain any more than a placebo in a small study, casting doubt on the potential for doctors to expand the medication's use.
Pfizer's Lyrica fails to outperform placebo in spinal stenosis study (PFE)  Seeking Alpha
Pfizer's (PFE) Lyrica No Better In Treating Most Common Back Pain  Bidness ETC
Related articles »  
Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B ...
PHILADELPHIA, Dec. 8, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the ...
Pfizer (PFE) Enters Gene Therapy Arena; Offers To Settle Class Action Over ...  Bidness ETC
Pfizer Inc. (NYSE:PFE) Announces Agreement  Street Report
Related articles »  
Pete Najarian Sees Unusual Options Activity In Pfizer
CNBC Fast Money's Pete Najarian said on the show that he is watching Pfizer Inc. (NYSE: PFE). He explained that it has been flat year-to-date, but its performance has been great in the last month.